<DOC>
	<DOCNO>NCT02414568</DOCNO>
	<brief_summary>This study evaluate bendamustine patient age 60 year classical Hodgkin Lymphoma treat prednisone , vinblastine doxorubicin . 90 patient enrol study .</brief_summary>
	<brief_title>Bendamustine Study Classical Hodgkin Lymphoma Patients Over 60 Treated Prednisone , Vinblastine Doxorubicin</brief_title>
	<detailed_description>The usual treatment Hodgkin lymphoma ABVD chemotherapy ( Adriamycin ( also know doxorubicin ) , Bleomycin , Vinblastine Dacarbazine ) . Studies show patient age 60 year low tolerance efficiency treatment young patient . There particular pulmonary toxicity bleomycin include ABVD treatment . Alternative treatment strategy propose remove bleomycin PVAG Protocol ( Prednisone , Vinblastine , Adriamycin/Doxorubicin Gemcitabine ) evaluate 60 patient . Compared ABVD treatment , PVAG treatment present favorable toxicity profile . The quality response two treatment substantially equal . Bendamustine evaluate four study patient Hodgkin lymphoma relapse show high efficacy gemcitabine acceptable toxicity profile . In study , Sponsor coordinate investigator propose replace dacarbazine standard ABVD protocol bendamustine stop use bleomycin . The main objective study evaluate safety efficacy bendamustine patient treat prednisone , vinblastine doxorubicin . This PVAB treatment LYSARC coordinate investigator expect good tolerability quality response .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patient first diagnosis classical Hodgkin lymphoma accord WHO criteria exclude nodular lymphocyte predominant subtype Age 61 year old No previous treatment Hodgkin lymphoma Ann Arbor stage : II mediastinum/thorax ≥0.33 extranodal localization B symptom Or III Or IV Baseline 18 ( FluoroDeoxyGlucose ) FDG PET scan ( PET0 ) perform treatment least one hypermetabolic lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate cardiopulmonary function Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % Adequate renal function creatinine clearance ≥ 40 mL/mn ( MDRD formula ) For patient age 70 year old , Mini Nutritional Assessment ( MNA ) ≥ 17 A minimum life expectancy 3 month Negative Human Immunodeficiency Virus , Hepatitis B Virus ( antiHBc negativity ) Hepatitis C Virus serologies test ≤ 30 day inclusion ( except vaccination ) Having previously sign write informed consent The patient must cover social security system , applicable Men patient must agree use adequate method contraception study treatment 6 month end study treatment . Any type lymphoma include nodular lymphocyte predominant subtype Any history treat Hodgkin lymphoma Contraindication drug contain chemotherapy regimens Any serious active disease ( accord investigator 's decision ) Poor hepatic function ( total bilirubin level &gt; 30 μmol/L transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma Poor bone marrow reserve define leukocyte &lt; 2 G/L platelet &lt; 100 G/L , unless relate bone marrow infiltration Any history cancer last 3 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Patients previously diagnose prostate cancer eligible fulfil following : 1. disease T1T2a , N0 , M0 , Gleason score ≤ 7 , prostate specific antigen ( PSA ) ≤ 10 ng/mL prior initial therapy , 2. definitive curative therapy ( i.e . prostatectomy radiotherapy ) ≥ 2 year Day 1 Cycle 1 , 3. minimum 2 year follow therapy , clinical evidence prostate cancer PSA undetectable underwent prostatectomy &lt; 1 ng/mL undergo prostatectomy Severe metabolic disease interfere normal application protocol treatment uncontrolled diabetes mellitus lead impossibility perform PET scan Treatment investigational drug within 30 day plan first cycle chemotherapy study Adult tutelage</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>